title: Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone.
abstract: Twenty-three women with premenstrual dysphoric disorder (PMDD) and 29 non-PMDD controls were compared for plasma progesterone (P) and its neuroactive steroid metabolite allopregnanolone (ALLO), as well as the ALLO/P ratio following the double-blind, placebo controlled administration of 300 mg oral micronized progesterone. Approximately half of each group had prior depression (DEP) (13 PMDD, 12 non-PMDD), though all were free of current depression. Progesterone and ALLO were sampled 160, 190, 225, and 255 min after progesterone administration. Changes over time in plasma concentrations and the ALLO/P ratio were assessed using area under the curve analyses. Women with prior DEP had lower ALLO levels (p=0.05) and marginally lower P levels (p<0.07) following progesterone administration compared to never depressed women, and this was especially evident in the non-PMDD women (p<0.01). PMDD women with no prior DEP had higher pre-progesterone ALLO/P ratios than all other groups (Ps<0.05) and higher ratios than the never depressed, non-PMDD women following oral progesterone (p<0.05). Results could not be accounted for by group differences in steroid hormone binding protein concentrations. For all women, progesterone administration was associated with increased confusion, fatigue, and with reduced confidence (Ps<0.01), even after controlling for placebo-associated mood change. These results suggest a persistent effect of prior DEP on P and ALLO concentrations following oral progesterone and that PMDD women, especially those with no prior DEP, may have alterations in the metabolic pathways underlying the conversion of P to ALLO.
authors.affiliation: Department of Psychology, University of North Carolina at Chapel Hill, CB #7175, Medical Research Bldg A, Chapel Hill, NC 27599-7175, USA.
authors.forename: Rebecca R
authors.initials: RR
authors.lastname: Klatzkin
authors.forename: A Leslie
authors.initials: AL
authors.lastname: Morrow
authors.forename: Kathleen C
authors.initials: KC
authors.lastname: Light
authors.forename: Cort A
authors.initials: CA
authors.lastname: Pedersen
authors.forename: Susan S
authors.initials: SS
authors.lastname: Girdler
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000339:Affect / Q000187:drug effects; D002214:Capsules; D018592:Cross-Over Studies; D003866:Depressive Disorder / Q000175:diagnosis*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D010919:Placebos; D011280:Pregnanolone / Q000097:blood*; D011293:Premenstrual Syndrome / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D011374:Progesterone / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D002214:Capsules; D010919:Placebos; D011374:Progesterone; D011280:Pregnanolone